Abstract
Gemcitabine is one of the most widely used pyrimidine analogues, with a well-established role as a first- and second-line treatment of several types of tumors. Several preclinical and clinical studies have been done to obtain information on molecular determinants of gemcitabine activity and metabolism, in order to predict whether this drug will be effective and safe for the individual patient. Among these molecular determinants, the mRNA and protein expression of equilibrative transporter-1 (ENT1) and ribonucleotide reductase (RR) emerged as possible predictors of drug activity in studies on pancreatic and non-small cell lung cancer. However, cytidine deaminase polymorphisms and activity were correlated with clinical outcome and severe toxicities, whereas further studies should evaluate both P53 dependent and independent pathways involved in gemcitabine induced apoptosis. Improved knowledge on these determinants is critical for the optimal development of combination of gemcitabine with other conventional or biological therapies, as well as to exploit the radiosensitizing potential of gemcitabine. Emerging technologies such as massive parallel sequencing, gene expression arrays and proteomics may identify novel biomarkers in tumor material, while polymorphisms and phenotyping analysis should unravel factors involved in drug toxicity. Validation of these markers in preclinical models should be used for the appropriate patient enrolment into subsequent prospective studies. Hopefully, novel pharmacogenetic biomarkers will be validated in these prospective studies and used to select cancer patients to be treated with gemcitabine-based regimens in the near future or to enroll them in studies with prodrugs in order to bypass resistance mechanisms.
Keywords: Gemcitabine, pharmacogenetics, equilibrative transporter-1, cytidine deaminase, drug combination, radiosensitization, polymorphisms, ribonucleotide reductase (RR), biomarkers, prodrugs
Current Pharmaceutical Design
Title:Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Volume: 18 Issue: 19
Author(s): Maha Elnaggar, Elisa Giovannetti and Godefridus J. Peters
Affiliation:
Keywords: Gemcitabine, pharmacogenetics, equilibrative transporter-1, cytidine deaminase, drug combination, radiosensitization, polymorphisms, ribonucleotide reductase (RR), biomarkers, prodrugs
Abstract: Gemcitabine is one of the most widely used pyrimidine analogues, with a well-established role as a first- and second-line treatment of several types of tumors. Several preclinical and clinical studies have been done to obtain information on molecular determinants of gemcitabine activity and metabolism, in order to predict whether this drug will be effective and safe for the individual patient. Among these molecular determinants, the mRNA and protein expression of equilibrative transporter-1 (ENT1) and ribonucleotide reductase (RR) emerged as possible predictors of drug activity in studies on pancreatic and non-small cell lung cancer. However, cytidine deaminase polymorphisms and activity were correlated with clinical outcome and severe toxicities, whereas further studies should evaluate both P53 dependent and independent pathways involved in gemcitabine induced apoptosis. Improved knowledge on these determinants is critical for the optimal development of combination of gemcitabine with other conventional or biological therapies, as well as to exploit the radiosensitizing potential of gemcitabine. Emerging technologies such as massive parallel sequencing, gene expression arrays and proteomics may identify novel biomarkers in tumor material, while polymorphisms and phenotyping analysis should unravel factors involved in drug toxicity. Validation of these markers in preclinical models should be used for the appropriate patient enrolment into subsequent prospective studies. Hopefully, novel pharmacogenetic biomarkers will be validated in these prospective studies and used to select cancer patients to be treated with gemcitabine-based regimens in the near future or to enroll them in studies with prodrugs in order to bypass resistance mechanisms.
Export Options
About this article
Cite this article as:
Elnaggar Maha, Giovannetti Elisa and J. Peters Godefridus, Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626175
DOI https://dx.doi.org/10.2174/138161212800626175 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients
Current Drug Safety Editorial (Thematic Issue: Antiangiogenic Agents in the Management of Solid Malignancies)
Current Angiogenesis (Discontinued) Cationized Albumin Conjugated Solid Lipid Nanoparticles as Vectors for Brain Delivery of an Anti-Cancer Drug
Current Nanoscience Peptide Sequence-Dominated Enzyme-Responsive Nanoplatform for Anticancer Drug Delivery
Current Topics in Medicinal Chemistry The Significance of Renal Function in Response to Cardiac Resynchronisation Therapy – A Piece of a Much Larger Puzzle
Current Vascular Pharmacology Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Editorial [Hot topic: Focal Adhesion Kinase Signaling in Cancer- Part II (Guest Editor: Vita M. Golubovskaya)]
Anti-Cancer Agents in Medicinal Chemistry Rethinking Pharmacogenomics Education Beyond Health Professionals: Addressing the “Know-Do” Gap Across the Personalized Medicine Innovation Ecosystem
Current Pharmacogenomics and Personalized Medicine IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells
Current Medicinal Chemistry Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design Nanocarriers for Respiratory Diseases Treatment: Recent Advances and Current Challenges
Current Topics in Medicinal Chemistry Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Local Drug Delivery Based Treatment Approaches for Effective Management of Periodontitis
Current Drug Therapy Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Meet Our Section Editor
Technology Transfer and Entrepreneurship (Discontinued) Anti-Inflammatory Drugs and Prediction of New Structures by Comparative Analysis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Oligonucleotide Aptamers for Glioma Targeting: An Update
Central Nervous System Agents in Medicinal Chemistry ABC Transporters and the Blood-Brain Barrier
Current Pharmaceutical Design Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology